000045423 000__ 01066cam\a22003855i\4500
000045423 001__ 45423
000045423 003__ SzGeWIPO
000045423 005__ 20240708150113.0
000045423 006__ m\\\\eo\\d\\\\\\\\
000045423 007__ cr bn |||m|||a
000045423 008__ 220328s2021\\\\nyu\\\\\o\\\\\000\0\eng\d
000045423 035__ $$a(OCoLC)1313806441
000045423 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000045423 041__ $$aeng
000045423 24500 $$a"Pith and marrow is dead... long live pith and marrow": The Doctrine of Equivalents after Actavis.
000045423 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2022
000045423 300__ $$a1 online resource
000045423 336__ $$atext$$2rdacontent
000045423 337__ $$acomputer$$2rdamedia
000045423 338__ $$aonline resource$$bcr$$2rdacarrier
000045423 4901_ $$aEuropean Intellectual Property Review,$$x0142-0461 ;$$vVolume 44, Issue 4
000045423 542__ $$fhttps://1.next.westlaw.com/Copyright
000045423 588__ $$aCrossref
000045423 590__ $$aPublished online: 2022
000045423 650_0 $$aIntellectual property
000045423 650_0 $$aCOVID-19 pandemic
000045423 650_0 $$aPatent law$$zEurope
000045423 7001_ $$aAoun, Wissam,$$eauthor.
000045423 7731_ $$tEuropean Intellectual Property Review
000045423 7731_ $$wEIPR
000045423 830_0 $$aEuropean Intellectual Property Review,$$vE.I.P.R. 2022, 44(4), 231-244
000045423 85641 $$uhttps://www.westlaw.com/Document/I11132FB0A58B11EC9D92EFEB3B33CB4E/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000045423 904__ $$aJournal article
000045423 980__ $$aEIPR